CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 646 enrolled
Drug / intervention
99mTc-PYP or 99m Tc-HDPdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03812172
NCT03812172N/ACompleted
CompareCT.gov

Screening for Cardiac Amyloidosis With Nuclear Cardiology for Minority Populations

Mathew S. Maurer, MD·observational·Posted Jan 23, 2019·Updated Nov 19, 2025

In Brief

An observational study evaluating 99mTc-PYP or 99m Tc-HDP for Amyloid Cardiomyopathy, Transthyretin-Related. Completed, enrolled 646 participants across 4 sites.

Detailed Summary

In this study, the investigators recruited a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators also explored differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloid Cardiomyopathy, Transthyretin-Related
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Boston Medical Center, Harlem Hospital Center, The Scripps Research Institute, Yale University

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 23, 2019
Enrollment StartMay 15, 2019
Primary CompletionJun 12, 2024
Study CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.4 years ago

Interventions

99mTc-PYP or 99m Tc-HDPdrug

10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) was administered intravenously and imaging was performed after 3 hours.